Blue Diamond Ventures, Inc. (OTCMKTS:BLDV) has all started with its preparations for September projects by announcing strategic additions. In the latest measures, the company has appointed Dr. Michele Ross as an advisor to company for guiding on medical breakthroughs, current clinical trials and synergies between patients, researchers and available therapies. She is the President, Executive Director and also founder of 501c3 nonprofit IMPACT Network.
Dr. Ross, as a neuroscientist, was unsatisfied by the lack of education on the endocannabinoid setup that both scientists and doctors received, irrespective of medical cannabis being utilized by millions of patients countrywide. In 2013, she established the “Endocannabinoid Deficiency Foundation,” which is now famous as IMPACT Network, with the objective to promote medical cannabis treatment a first line treatment for patients by educating healthcare professionals, policy makers and patients and supporting clinical cannabis research
Another addition to Blue Diamond’s team is Joseph Groleau, who joins as an advisor to company for Canadian Business Ventures & Grow Operations. Third addition to the team is Richard Paniagua who joins the Advisory Board of company with diverse investment, venture capital, and operational management experience including import/export, real estate, agriculture and software development.
In other news, the company reported that Kenneth Teknus will be resigning from his role of Consultant to Blue Diamond. He will no longer be linked with the firm. The management appreciated Teknus efforts for his team with company and wished him the best for his future plans. As it is known, Blue Diamond looks to associate with individuals and firms that share a common synergy, objective and vision to enable products and services that are produced, supplied and expended using fewer natural resources.
In the last trading session, the stock price of Blue Diamond gained 0.08% to close the day at $0.00240. The gains came at a share volume of 20.16 million compared to average share volume of 27.38 million.
Top Stock Analysis At Journal Transcripthttp://www.journaltranscript.com
Early bird alerts on the hottest OTC companies
2017 Most Disruptive Biotech VBIOhttp://www.financialstrend.com
Disruptive biotech VBIO decodes targeted drug delivery for stem cells
Can CBD Oil Get Rid of Chronic Pain?http://www.greenleaf.farm
Pure Colorado Golden CBD Oil Hemp Extracts